Dronedarone Hydrochloride (HCID 219025)

Überblick

Dronedarone Hydrochloride is the hydrochloride salt form of dronedarone, an orally bioavailable benzofuran derivative, with anti-arrhythmic activity. Upon oral administration, and although the exact mechanism of action through which dronedarone exerts its anti-arrhythmic effect has not been fully elucidated, it inhibits multiple voltage-gated ion channels, including sodium, potassium, and calcium ion channels, and restores the normal sinus rhythm and reduces heart rate in atrial fibrillation. It also non-competitively antagonizes adrenergic receptors.

Namen und Bezeichner

Bevorzugter Name: Dronedarone Hydrochloride
IUPAC: N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide;hydrochloride
Englischer Name: Dronedarone hydrochloride
Summenformel: C31H44N2O5S.ClH
Molmasse: 593.22

Namen und Synonyme

Dronedarone hydrochloride141625-93-6Dronedarone HClSR33598BUNII-FA36DV299QFA36DV299QN-(2-Butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide monohydrochlorideDTXSID30161779DRONEDARONE HYDROCHLORIDE [EP MONOGRAPH]N-(2-Butyl-3-(4-(3-(dibutylamino)proproxy)benzoyl)benzofuran-5-yl) methanesulfonamide-, monohydrochlorideDRONEDARONE HYDROCHLORIDE (MART.)DRONEDARONE HYDROCHLORIDE [MART.]

Weitere Namen anzeigen

Dronedarone hydrochloride, ≥98% (HPLC)MultaqCS-132SR33589SR-33589BCAS:141625-93-6DRONEDARONE HCl CAS:Multaq Hydrochloride.SR33589 Hydrochloride

DRONEDARONE HYDROCHLORIDE (USP-RS)DRONEDARONE HYDROCHLORIDE [USP-RS]Methanesulfonamide, N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-, monohydrochlorideDRONEDARONE HYDROCHLORIDE (EP MONOGRAPH)DRONEDARONE HYDROCHLORIDE (USP MONOGRAPH)DRONEDARONE HYDROCHLORIDE [USP MONOGRAPH]Methanesulfonamide, N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]-, monohydrochlorideRefChem:55074

Datenbank-Bezeichner

CAS: 141625-93-6
PubChem CID: 219025
DTXSID: DTXSID30161779
ChEMBL: CHEMBL1201729
UNII: FA36DV299Q
EC Number: 630-355-2

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA): 97,2 Å²
H-Brücken-Donoren: 2
H-Brücken-Akzeptoren: 7
Frei drehbare Bindungen: 18
Schwere Atome: 40
Formalladung: 0
Komplexität: 800

Experimentelle und physikochemische Eigenschaften

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt: NA (low-melting)
storage temp.: 2 · 2-8°C
Löslichkeit: 15 mg/mL, · DMSO: soluble15mg/mL, clear
Aggregatzustand: powder
Farbe: white to off-white
Merck: 14 · 14,3449
Stabilität: Hygroscopic
InChIKey: DWKVCQXJYURSIQ-UHFFFAOYSA-N
SMILES: Cl.CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c2c(CCCC)oc3ccc(NS(C)(=O)=O)cc23

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 8.3% (1 of 12) of reports.

Warning

H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (33.3%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Dronedarone hydrochloride

vMost-DILI-concern

7

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

wgk: 3
ridadr: UN 3077 9 / PGIII
hs_code: 2935904000
Speicherklasse: 11 - Combustible Solids

Chemie und Industrie

Anwendungen · 2 Einträge

HistoryDRONEDARONE HYDROCHLORIDE (brand name: Multaq) is an antiarrhythmic drug developed by Sanofi-Aventis. It was approved by the FDA in July 2009 for the treatment of atrial fibrillation and atrial flutter, reducing the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL). The drug was developed to create a treatment that maintains the therapeutic benefits of amiodarone while reducing associated serious side effects such as pulmonary toxicity and thyroid dysfunction. DRONEDARONE HYDROCHLORIDE is usually administered orally in tablet form. The recommended dose is 400 mg twice daily, one tablet in the morning and one in the evening.

VerwendenDronedarone Hydrochloride can be used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.